Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy.

The wide range of novelties reported in this Special Issue of the journal I Cells i on prostate cancer (PCa) diagnosis, prognosis, and prediction to response to therapy, has led us to a series of considerations related to a better understanding of the current and future role of effective molecular biomarkers in individual patients with PCa [[1], [3], [5], [7]]: (1) Digital pathology, including multiplexing; (2) Clinical translation of genetic information; (3) Clinical significance of liquid biopsies; and (4) Multi-criteria decision making and information fusion. The genomic analysis of cell-free DNA and circulating tumor cells (liquid biopsy) is an attractive alternative to sequential tissue biopsies [[12]] (See below: I Clinical significance of liquid biopsy i ). The resulting information, including the diagnostic and therapeutic approaches and decisions, when applied to PCa, for instance, examined with large format histology and whole-slide imaging [[17]], and with multiple biomarkers derived from tissue, urine, and blood samples, is far more accurate than when the various sources are evaluated separately and individually [[18]]. [Extracted from the article]